Bridged Morpholine Monoamine Releasers With Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for mental health disorders and CNS disorders, such as psychotherapy and pharmacotherapy, suffer from significant drawbacks, including limited availability and severe side effects, leading to inadequate treatment access and efficacy.
Innovation Solution
Development of novel substituted heterocyclic bridged ring compounds, including morpholine and piperidine derivatives, that stimulate monoamine neurotransmitter release and inhibit transporter function, formulated into pharmaceutical compositions for oral, buccal, sublingual, injectable, subcutaneous, intravenous, or transdermal administration, optionally combined with additional active agents to enhance therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacotherapy options (SSRIs) are used to treat mental health disorders, then treatment coverage is provided, but side effects are severe and treatment access is limited
Solution Approach 1:
The patent segments the treatment approach by developing novel compounds with specific molecular structures (Formula 1 and Formula 2) that selectively target monoamine transporters. This segmentation allows for differentiated pharmacological action compared to conventional SSRIs, aiming to achieve therapeutic effects with reduced side effect profiles through structure-activity relationship optimization.
Solution Approach 2:
The patent applies parameter changes by modifying key molecular parameters including the heterocyclic ring structure (morpholine, thiomorpholine, piperidine), substituent groups (R1, R2, R3), and bridge configurations. These structural parameter changes are designed to optimize the balance between therapeutic efficacy and side effect reduction by fine-tuning the compounds' interaction with monoamine transporters.
2Ease of operation
If current treatment options are made more accessible, then treatment coverage increases, but the fundamental lack of therapeutically effective options remains
Solution Approach 1:
The patent employs self-service principles by designing compounds with optimized pharmacokinetic properties including oral bioavailability, appropriate half-life, and metabolic stability. The compounds are designed to be self-administerable formulations that maintain therapeutic levels without requiring complex delivery systems, thereby improving accessibility while maintaining effectiveness.
Solution Approach 2:
The patent achieves universality by developing a broad class of compounds (Formula 1 and Formula 2 with multiple substituents and heterocyclic variations) that can address multiple mental health conditions through common monoamine mechanisms. This multi-functional approach allows a single compound class to potentially treat depression, anxiety, PTSD, and other disorders, expanding treatment accessibility across diverse conditions.
3Reliability
If psychotherapy and pharmacotherapy are combined, then treatment comprehensiveness improves, but complexity of treatment regimen increases
Solution Approach 1:
The patent applies merging principles by combining multiple therapeutic mechanisms within single molecular structures. The compounds simultaneously exhibit monoamine releasing activity and transporter inhibition properties, effectively merging what would traditionally require multiple separate medications into one unified pharmacological agent, thereby reducing regimen complexity while maintaining comprehensiveness.
Solution Approach 2:
The patent uses parameter changes to optimize the dual mechanism of action by adjusting molecular parameters such as basicity of the nitrogen atom, lipophilicity, and molecular size. These parameter optimizations allow the compounds to achieve both releasing and inhibiting effects with appropriate potency ratios, simplifying the treatment approach while maintaining comprehensive therapeutic coverage.
Data Source
AI summary
Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such compounds, and methods of their use to treat mental health disorders and CNS disorders.